Apricus Biosciences, Inc.
21.11.2012 12:30
---------------------------------------------------------------------------
SAN DIEGO, 2012-11-21 12:30 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(www.apricusbio.com) announced today that Steve Martin, Interim Chief Executive
Officer and Chief Financial Officer, will present at the 24th Annual Piper
Jaffray Healthcare Conference, being held at the New York Palace Hotel in New
York City. Mr. Martin's presentation will take place on Tuesday, November 27,
2012 at 4:30 p.m. Eastern Time.
The presentation will be webcast and accessible to the public online at
http://www.media-server.com/m/p/m3w45839 or via the Company's website at
http://www.apricusbio.com. A replay will be available for 90 days after the
presentation.
About Apricus Biosciences, Inc.
Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that develops and markets
innovative treatments that help large patient populations across numerous,
high-demand therapeutic classes. The Company has three approved products and
has developed a strong pipeline of multiple late-stage product candidates. With
commercial operations in both the U.S. and Europe (France), Apricus Bio
generates revenues and growth from sales of its commercial products and by
out-licensing, in certain territories, its pipeline products and NexACT(r)
technology.
Apricus Bio's growth strategy is to acquire, develop, and commercialize new
products through strategic partnerships. The Company currently has commercial
partnerships with multiple large pharmaceutical companies including Novartis,
Takeda, Abbott Laboratories, Sandoz, Warner Chilcott, and Bracco, and
co-promotes multiple products in France.
Apricus Bio is headquartered in San Diego, CA and is publicly traded on the
NASDAQ Capital Market under the ticker symbol APRI.
For further information on Apricus Bio, visit http://www.apricusbio.com, and
for information on its subsidiary please visit http://www.nexmedusa.com. You
can also receive information at http://twitter.com/apricusbio.
CONTACT: Apricus Bio Investor Relations:
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
News Source: NASDAQ OMX
21.11.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
DGAP-News: Apricus Biosciences to Present at the 24th Annual Piper Jaffray Healthcare Conference
| Source: EQS Group AG